Needham Maintains Their Hold Rating on BioCryst (BCRX)

By Jason Carr

In a report released today, Serge Belanger from Needham maintained a Hold rating on BioCryst (BCRXResearch Report). The company’s shares closed last Monday at $2.04, close to its 52-week low of $1.95.

According to TipRanks.com, Belanger is a 1-star analyst with an average return of -1.5% and a 41.7% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Collegium Pharmaceutical, KalVista Pharmaceuticals, and Zynerba Pharmaceuticals.

BioCryst has an analyst consensus of Moderate Buy, with a price target consensus of $13.00.

See today’s analyst top recommended stocks >>

The company has a one-year high of $9.95 and a one-year low of $1.95. Currently, BioCryst has an average volume of 1.4M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

BioCryst Pharmaceuticals, Inc. designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases. Its drug candidates include rapivab, alpivab, rapiacta, peramiflu, BCX7353, BCX9930, BCX9250, Galidesivir, and Mundesine. The company was founded in 1986 and is headquartered in Durham, NC.